Printer Friendly

ROBERTS PHARMACEUTICALS ANNOUNCES SIGNING OF MERGER AGREEMENT WITH HAUCK PHARMACEUTICALS

              ROBERTS PHARMACEUTICALS ANNOUNCES SIGNING OF
              MERGER AGREEMENT WITH HAUCK PHARMACEUTICALS
    EATONTOWN, N.J., Nov. 6 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ: RPCX) announced today that it has signed a definitive merger agreement with W.E. Hauck, Inc. of Alpharetta, Ga. The total purchase price of the acquisition is approximately $7.6 million, consisting of approximately $2 million in cash with the balance in shares of Roberts Pharmaceuticals common stock. The transaction is subject to the approval of the Hauck shareholders and satisfaction of other conditions of closing.  A registration statement will be filed by Roberts to cover the issuance of the common stock in the near future.  The offering of the common stock to the Hauck shareholders will be made only by means of a prospectus.  A letter of intent regarding this acquisition was previously announced.
    Hauck was founded in 1975 by its president, Warren E. Hauck.  The company's primary products include ENTUSS(TM) (cough/cold treatment), CHLORAFED(R) (antihistamine), SINUFED(TM) (expectorant), and DOLACET(TM) (analgesic).  Hauck distributes over 40 ethical pharmaceutical products and over 50 industrial medical products.  The company has approximately 50 employees and its sales force is concentrated east of the Mississippi from New England to Florida.  The Hauck group of companies, which includes Hauck Pharmaceuticals, Mallard Pharmaceuticals and a majority interest in Geriatric Pharmaceutical, produced net sales of over $4 million for the fiscal year ended June 30, 1991.
    Roberts Chairman and CEO, Dr. Robert A. Vukovich, stated, "Our detailed review of the Hauck organization and product lines continues to support our belief that a significant strategic fit exists between our companies.  As a result, Roberts marketing and sales capabilities will be substantially enhanced by the addition of 30 sales representatives to our existing sales force.  The Hauck product line complements Roberts existing products and this will enable Roberts to effectively increase sales effort for our current prescription and non-prescription products lines.  It is expected that the overall growth of the Roberts and Hauck product lines will be improved by the combination of operational synergies and focused management effort. In addition to the current advantages of the acquisition, there is an excellent fit with Roberts R&D pipeline, especially in the respiratory and pain management therapeutic areas."
    Roberts Pharmaceutical Corporation is in the business of acquiring, developing, and marketing human pharmaceuticals in the United States and abroad.  The company is developing late stage pharmaceuticals for the treatment of cancer, respiratory disease, endocrine disorders, pain management, cardiovascular and urologic conditions.  The company has a range of products which it sells in the United States and abroad including a line of prescription pharmaceuticals which includes FURACIN(R), for burn wounds, and FUROXONE(R), an intestinal anti- bacterial.  Non-prescription pharmaceuticals marketed by the company include CHERACOL(R) cough/cold products, HALTRAN(R) for menstrual disorders, and PYRROXATE(R) for sinus/allergy conditions.
    -0-        11/6/91
    /CONTACT:  Anthony P. Maris of Roberts Pharmaceuticals, 908-389-1182/
    (RPCX) CO:  Roberts Pharmaceutical Corporation; W.E. Hauck, Inc. ST:  New Jersey, Georgia IN:  MTC SU:  TNM TS-JT -- NY038 -- 1672 11/06/91 11:54 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 6, 1991
Words:511
Previous Article:MID-STATE FEDERAL ANNOUNCES RESULTS FOR YEAR AND FOURTH QUARTER
Next Article:GWC CORPORATION REPORTS THIRD QUARTER 1991 EARNINGS
Topics:


Related Articles
YAMANOUCHI TO PURCHASE EQUITY POSITION IN ROBERTS PHARMACEUTICALS
/C O R R E C T I O N -- ROBERTS PHARMACEUTICALS/
ROBERTS PHARMACEUTICALS COMPLETES ACQUISITION OF HAUCK PHARMACEUTICALS
ROBERTS PHARMACEUTICALS TO ACQUIRE MARKETED RESPIRATORY DRUG FROM SMITHKLINE BEECHAM
ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES PRODUCT ACQUISITION AGREEMENT WITH BRISTOL-MYERS SQUIBB
ROBERTS PHARMACEUTICAL CORPORATION COMPLETES PRODUCT ACQUISITION FROM GLAXO CANADA INC.
ROBERTS PHARMACEUTICAL CORPORATION COMPLETES ACQUISITION OF U.S. AND CANADIAN PRODUCT LINES FROM BRISTOL-MYERS SQUIBB
ROBERTS PHARMACEUTICAL COMPLETES UNITED KINGDOM PRODUCT ACQUISITION FROM PROCTER & GAMBLE
Walsh International Shareholders Approve Acquisition by Cognizant
Shire Pharmaceuticals Group plc to Merge With Roberts Pharmaceutical Corporation.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters